Show Search Form

Search Results

type
answer	answer text answering member
tabling member	label

Search

1010153

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>This information is not available by local authority.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1012292

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The Government supports the principle that creators should be fairly rewarded for their work whilst ensuring that we continue to encourage investment in new content and innovative services. We are engaging with our European partners to achieve these aims during Trilogue negotiations on this Directive.</p> answering member 3980
	tabling member	1436 label Biography information for Paul Farrelly

1012293

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The Government has considered this issue in the context of its Brexit analysis. It has concluded that the reciprocal arrangements between UK Collective Management Organisations (CMOs) and EU CMOs to collect royalties from EU countries and distribute to creators in the UK are private commercial agreements which are expected to continue after the UK has exited the European Union.</p> answering member 3980
	tabling member	1436 label Biography information for Paul Farrelly

1012294

	type	WrittenParliamentaryQuestion
	answer	answer answer text The UK will always be a European country that advocates for cultural diversity as part of its global identity and is committed to continuing its contribution to and support of European culture. The Government has been clear that will be explore participation in any successor programme to Creative Europe. Where EU funding programmes are to the UK and EU's joint advantage, we want to discuss continued participation as part of the negotiations. Ultimately, the decision on which programmes are in the UK’s interests will be decided as part of the future partnership negotiations, which are ongoing. answering member 4115
	tabling member	1436 label Biography information for Paul Farrelly

1016320

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will ensure that access to medicines and medical devices continues, and patient safety is maintained, in both the United Kingdom and European Union markets.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be the UK competent authority during this period.</p><p> </p><p>For medical devices, CE marks are assigned by notified bodies (rather than competent authorities such as the MHRA), and during the implementation period UK notified bodies will continue to conduct third-party conformity assessment in the UK, and the results of these tests will continue to be used and recognised for both the UK and EU markets.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1020404

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as a European Union competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p> </p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p> </p><p>It is possible for a single organisation to have individual notified bodies designated in more than one Member State. The authority within each Member State is responsible for notified bodies based in its own country.</p><p> </p><p>The MHRA is responsible for the designation and monitoring of notified bodies in the United Kingdom, which the response to Question 196736 refers to.</p> answering member 4065
	tabling member	1436 label Biography information for Paul Farrelly

1020405

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The agreement of an implementation period will mean that the Medicines and Healthcare products Regulatory Agency (MHRA) will continue to be recognised as an EU competent authority designated under the EU Directives for medical devices, in vitro diagnostic medical devices and active implantable medical devices, during this period.</p><p>This is also the case for the new EU Regulations for medical devices and in vitro diagnostic medical devices, which both entered into force in May 2017.</p><p><strong></strong><br><br></p><p> </p> answering member 3977
	tabling member	1436 label Biography information for Paul Farrelly

179157

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>As part of NHS England, NHS Trust Development Authority (TDA) and Monitor’s joint project to support 11 challenged local health economies develop clinically and financially sustainable five-year strategic plans, four consultancy firms (including KPMG) were commissioned to support the local areas with the development and strengthening of their plans.</p><p> </p><p> </p><p> </p><p>Reports were provided by the consultants to support the project’s Programme Board, consisting of NHS England, TDA and Monitor, to manage the contracts and ensure that the service specification was being met.</p><p> </p><p> </p><p> </p><p>Work is ongoing based on the contents of these reports and there are a number of steps that have to be undertaken in each of the local health economies before these reports can be released: the production of the five-year strategic plan, consideration of the plan, consultation on possible reforms to the health economy, recommendations for possible reforms following consultation, and implementation of recommendations.</p><p> </p><p> </p><p> </p><p>To release the reports ahead of the steps identified above being completed would be likely to prejudice their outcome. The timescales for the above processes will be different in each of the 11 areas and, as the strategic plans are produced, they are made available from the relevant clinical commissioning group websites through their board papers.</p><p> </p> answering member 3918
	tabling member	1436 label Biography information for Paul Farrelly

179165

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>As part of NHS England, NHS Trust Development Authority (TDA) and Monitor’s joint project to support 11 challenged local health economies develop clinically and financially sustainable five-year strategic plans, four consultancy firms (including KPMG) were commissioned to support the local areas with the development and strengthening of their plans.</p><p> </p><p> </p><p> </p><p>Reports were provided by the consultants to support the project’s Programme Board, consisting of NHS England, TDA and Monitor, to manage the contracts and ensure that the service specification was being met.</p><p> </p><p> </p><p> </p><p>Work is ongoing based on the contents of these reports and there are a number of steps that have to be undertaken in each of the local health economies before these reports can be released: the production of the five-year strategic plan, consideration of the plan, consultation on possible reforms to the health economy, recommendations for possible reforms following consultation, and implementation of recommendations.</p><p> </p><p> </p><p> </p><p>To release the reports ahead of the steps identified above being completed would be likely to prejudice their outcome. The timescales for the above processes will be different in each of the 11 areas and, as the strategic plans are produced, they are made available from the relevant clinical commissioning group websites through their board papers.</p><p> </p> answering member 3918
	tabling member	1436 label Biography information for Paul Farrelly

223300

	type	WrittenParliamentaryQuestion
	answer	answer answer text <p>The work to support the 11 challenged health economies was commissioned jointly by Monitor, NHS Trust Development Authority and NHS England.</p><p> </p><p> </p><p> </p><p>Consultancy firms were not commissioned to produce reports on the local health economies, as described in the question, but to support the local health economies with the development and strengthening of their strategic plans.</p><p> </p> answering member 3918
	tabling member	1436 label Biography information for Paul Farrelly